Stocksigma LogoStocksigma Logo

Q-Line Biotech Discloses IPO Proceeds Utilization and 70% Acquisition of Heidelco Medicore

CARE Ratings issued Q-Line Biotech's monitoring report for the half-year ended 30th Sep'26, showing utilization of Rs 122.34 crore out of Rs 214.48 crore

Q-Line Biotech Discloses IPO Proceeds Utilization and 70% Acquisition of Heidelco Medicore

Q-Line Biotech Ltd 路 Others (Uncategorized) 路 13 Nov 2026, 2:40 am

Q-Line Biotech Discloses IPO Proceeds Utilization and 70% Acquisition of Heidelco Medicore CARE Ratings issued Q-Line Biotech's monitoring report for the half-year ended 30th Sep'26, showing utilization of Rs 122.34 crore out of Rs 214.48 crore gross IPO proceeds, with Rs 92.14 crore parked in fixed deposits. A prior Rs 0.98 crore deviation in debt-prepayment charges was reversed and restored. Separately, the board approved acquiring a 70% stake in Heidelco Medicore Private Limited for Rs 26.64 crore in cash, expanding its critical care instruments and consumables business. Heidelco posted H1FY27 turnover of Rs 57.63 crore and PAT of Rs 3.02 crore.

Original exchange filing (PDF)

More announcements from Q-Line Biotech Ltd

All Q-Line Biotech Ltd announcements